Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130983 · ClinicalTrials.gov registry record · Phase 1
Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease
A Phase 1 study, sponsored by Direct Biologics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05130983 is a Phase 1 study that was terminated before completion, run by Direct Biologics. The registered enrollment target is 3 participants.
The verdict
NCT05130983, a Phase 1 study, was terminated before completion, sponsored by Direct Biologics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Protocol Summary * Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory Crohn's disease. * Short Title: ExoFlo for Crohn's Disease * Phase: 1 * Methodology: Open label * Study Duration: 24 months * Subject Participation: 58 weeks * Single or Multi-Site: Multi-Site
Interventions
- BIOLOGICAL ExoFlo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05130983
The ClinicalTrials.gov registry entry for NCT05130983 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Direct Biologics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExoFlo is the first listed.
NCT05130983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05130983 about?
NCT05130983 is a clinical study titled "Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease". Protocol Summary * Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory Crohn's disease. * Short Title: ExoFlo for Crohn's Disease * Phase: 1 * Method...
What is the current status of trial NCT05130983?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-01-23. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT05130983?
The interventions under investigation include: ExoFlo (BIOLOGICAL).
Who is sponsoring clinical trial NCT05130983?
This trial is sponsored by Direct Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.